Epkinly
Novel Therapy Shows Impressive Activity in Heavily Pretreated CLL
As an alternative to the targeted therapies now commonly used in relapsed/refractory (R/R) chronic lymphocytic ...
FEBRUARY 24, 2025
FDA Grants Accelerated Approval to Epkinly for Relapsed or Refractory Follicular Lymphoma
The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab U.S.), a bispecific CD20-directed CD3 ...
JUNE 27, 2024
Epkinly Approved for Relapsed/Refractory Diffuse Large B-cell Lymphoma and High-Grade B-Cell Lymphoma
The FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab) for relapsed/refractory diffuse large ...
MAY 22, 2023
Load more